Salvador Moncada - Scientific Contributions

Scientific Contributions

His scientific career began at the Royal College of Surgeons where he collaborated in the discovery that aspirin-like drugs inhibit prostaglandin biosynthesis. This finding elucidated the mechanism by which these drugs act as analgesic, antipyretic and anti-inflammatory agents and also explained the mechanism by which they cause gastric damage. In 1975, at the Wellcome Research Laboratories, he led the team that discovered the enzyme thromboxane synthase and the vasodilator prostacyclin. This work contributed to the understanding of how low doses of aspirin prevent cardiovascular episodes such as myocardial infarction and stroke. As Director of Research at the Wellcome Research Laboratories he presided over the discovery and development of lamotrigine (an anti-epileptic compound), atovaquone (an anti-malarial) and zomig (for treatment of migraine headaches), and initiated the work that resulted in the development of lapatinib for the treatment of breast cancer. He was also responsible for the identification of nitric oxide as a biological mediator and the elucidation of the metabolic pathway leading to its synthesis. A great deal of the early work on the biological significance of nitric oxide in the cardiovascular system came from his laboratory, as well as some fundamental information about the role of nitric oxide in the peripheral and central nervous system and in cancer. His later work has focused on the areas of mitochondrial biology and cell metabolism. Most recently, his work has led to the finding of the molecular mechanism that coordinates cell proliferation with the provision of metabolic substrates required for this process.